Summary:
- Pulnovo Medical, a Hong Kong-based company specializing in medical devices for pulmonary hypertension and heart failure, secured new investment from EQT Group with support from Qiming Venture Partners.
- The investment will aid in global expansion, clinical trials, regulatory approvals, and commercialization efforts following the company’s recent CE-MDR certification in Europe.
- Pulnovo Medical, founded in 2013, focuses on pulmonary artery denervation technology and has received various regulatory approvals and designations for its groundbreaking medical devices.
Article:
Pulnovo Medical Secures New Investment to Advance Treatment for Pulmonary Hypertension and Heart Failure
Pulnovo Medical, a leading company in the field of medical devices for pulmonary hypertension (PH) and heart failure (HF), has recently received a significant investment from EQT Group, with continued support from Qiming Venture Partners. This new investment is expected to drive the company’s global expansion and accelerate the development and commercialization of its innovative treatment options for patients with PH.
The exact amount of the investment has not been disclosed, but it comes on the heels of Pulnovo Medical’s recent CE-MDR certification in Europe. This certification marks a major milestone for the company, opening up new opportunities for international clinical trials, regulatory approvals, and commercialization efforts.
Founded in 2013 by Cynthia Chen, Pulnovo Medical focuses on addressing the critical unmet needs in cardiovascular care through its groundbreaking medical devices based on pulmonary artery denervation (PADN) core technology. The company has received various accolades and regulatory approvals, including the US FDA Breakthrough Device designation and FDA Humanitarian Use Device designation.
In addition, Pulnovo Medical’s products have received China NMPA Approval as a breakthrough device and FDA clearance for their 9F sheath. With the recent CE-MDR certification, the company is well-positioned for global commercialization and further advancements in the treatment of PH and HF.
Overall, Pulnovo Medical’s new investment from EQT Group and ongoing support from Qiming Venture Partners signal a bright future for the company as it continues to innovate and expand its reach in the field of medical devices for cardiovascular care.
